Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- N/A
M&A news:
- RIO +0.6% (Rio Tinto confirms Yancoal as the preferred buyer of its thermal coal assets in Australia)
Other news:
- SRNE +15.9% (successful Phase 1 / 2 pharmacokinetic bridging trial of the lead product SP-102)
- STOR +8.9% (announces that Berkshire Hathaway (BRK.A/B) has invested $377 mlnin the company, representing 9.8% of total shares outstanding)
- CBIO +4.9% (positive preclinical results of CB 2679d/ISU304)
- AVEO +4.8% (continued strength)
- TGTX +3.7% (recaps preliminary results from its ongoing Phase 2 study of TG-1101)
- CNAT +3.7% (confirms being granted Orphan Drug Designation by the FDA for IDN-7314)
- P +2.5% (CEO Tim Westergren plans to leave the company, according to ReCode)
- AMD +1.3% (continued strength following last weeks 25% rise)
- MOMO +1.1% (continued strength)
Analyst comments:
- PTLA +4.1% (target raised to $70 from $50 at Morgan Stanley)
- MU +2.1% (target raised to $40 from $32.50 at Wells Fargo)
- CS +1.6% (resumed with a Overweight at JP Morgan)
- COH +1.6% (upgraded to Buy from Neutral at Buckingham Research)
- UBS +1.2% (upgraded to Overweight from Neutral at JP Morgan)
- COST +1.1% (upgraded to Outperform from Mkt Perform at Raymond James)